Zobrazeno 101 - 110
of 624
pro vyhledávání: '"Yuqin Song"'
Autor:
Toby A Eyre, Nirav N Shah, Martin Dreyling, Wojciech Jurczak, Yucai Wang, Chan Y Cheah, Yuqin Song, Mitul Gandhi, Christopher Chay, Jeff Sharman, David J Andorsky, Hannah M Messersmith, Amy S Ruppert, Valerie A Muthig, Rodrigo Ito, Michael L Wang
Publikováno v:
Future Oncology. 18:3961-3969
Treatment with covalent Bruton tyrosine kinase inhibitors (BTKi) represents an important advance in the management of relapsed or refractory mantle cell lymphoma, but these treatments are not curative and many patients ultimately relapse. Pirtobrutin
Autor:
Hongye, Gao, Yanfeng, Xu, Yanfei, Liu, Lan, Mi, Xiaopei, Wang, Weiping, Liu, Jun, Zhu, Yuqin, Song
Publikováno v:
Cancer Management and Research. 14:2711-2721
Hongye Gao,* Yanfeng Xu,* Yanfei Liu, Lan Mi, Xiaopei Wang, Weiping Liu, Jun Zhu, Yuqin Song Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Inst
Autor:
Hui Yu, Lan Mi, Weimin Zhang, Yingying Ye, Miaomiao Li, Dingyao Hu, Jiaowu Cao, Dedao Wang, Xiaogan Wang, Ning Ding, Yuqin Song, Jun Zhu
Publikováno v:
Hematological Oncology. 40:894-905
Aberrant activity of histone deacetylases (HDACs) is frequently detected in B-cell lymphomas, which indicated the therapeutic implications of HDAC inhibitors for B-cell malignancies. We have discovered that lymphoma cells treated with HDAC inhibitor
Autor:
Wei Xu, Shenmiao Yang, Constantine S. Tam, John F. Seymour, Keshu Zhou, Stephen Opat, Lugui Qiu, Mingyuan Sun, Tingyu Wang, Judith Trotman, Ling Pan, Sujun Gao, Jianfeng Zhou, Daobin Zhou, Jun Zhu, Yuqin Song, Jianda Hu, Ru Feng, Haiwen Huang, Dan Su, Miao Shi, Jianyong Li
Publikováno v:
Advances in Therapy. 39:4250-4265
Zanubrutinib is a highly selective irreversible inhibitor of Bruton tyrosine kinase which has shown significant activity in lymphoid malignancies in early phase studies. We report here the long-term follow-up outcomes of zanubrutinib in various lines
Autor:
Yuqin, Song, Yanyan, Liu, Zhi-Ming, Li, Lanfang, Li, Hang, Su, Zhengming, Jin, Xuelan, Zuo, Jianyuan, Wu, Hui, Zhou, Kunyan, Li, Chuan, He, Jianfeng, Zhou, Junyuan, Qi, Siguo, Hao, Zhen, Cai, Yijing, Li, Weiwei, Wang, Xiaojing, Zhang, Jianjun, Zou, Jun, Zhu
Publikováno v:
The Lancet Haematology. 9:e493-e503
Dysregulation of EZH2 has a crucial role in lymphomagenesis. We did a first-in-human study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of SHR2554, an oral EZH2 inhibitor, in patients with relapsed or re
Autor:
Michael L, Wang, Wojciech, Jurczak, Mats, Jerkeman, Judith, Trotman, Pier L, Zinzani, David, Belada, Carola, Boccomini, Ian W, Flinn, Pratyush, Giri, Andre, Goy, Paul A, Hamlin, Olivier, Hermine, José-Ángel, Hernández-Rivas, Xiaonan, Hong, Seok Jin, Kim, David, Lewis, Yuko, Mishima, Muhit, Özcan, Guilherme F, Perini, Christopher, Pocock, Yuqin, Song, Stephen E, Spurgeon, John M, Storring, Jan, Walewski, Jun, Zhu, Rui, Qin, Todd, Henninger, Sanjay, Deshpande, Angela, Howes, Steven, Le Gouill, Martin, Dreyling, Joseph C, Gardiner
Publikováno v:
New England Journal of Medicine. 386:2482-2494
Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma.We randoml
Autor:
Lugui Qiu, Zusheng Xu, Hanying Bao, Shuhua Yi, Zengjun Li, Lihong Liu, Weiliang Zhu, Xuekui Gu, Weixin Wu, Fei Li, Jie Jin, Weijun Fu, Zhihui Zhang, Zhen Cai, Hong Cen, Zhifeng Li, Yu Yang, Hui Zhou, Keshu Zhou, Junmin Li, Wei Zhang, Huijing Wu, Dengju Li, Li Zhang, Yuqin Song, Zhiming Li, Junning Cao, Hang Su, Lihua Qiu, Xiuhua Sun, Tingyu Wang
List of participating hospitals for the clinical trial NCT04370405
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69e6241f39607ab717a1059df55b5b20
https://doi.org/10.1158/1078-0432.22633091
https://doi.org/10.1158/1078-0432.22633091
Autor:
Jie Che, Zhaoran Wang, Yuqin Song, Hongxia Guan, Min Yuan, Xia Chen, Xiaofei Zhao, Yong Xiao, Yunfei Zhang, Dan Sha, Chao Wang, Jie Feng, Juan Li
Publikováno v:
Microbiology Spectrum. 11
IMI carbapenemases have been detected in clinical isolates of many bacterial species with systemic infection and cause a further burden on clinical treatment in China, but their source and distribution are still unclear. The study systematically inve
Autor:
Lugui Qiu, Zusheng Xu, Hanying Bao, Shuhua Yi, Zengjun Li, Lihong Liu, Weiliang Zhu, Xuekui Gu, Weixin Wu, Fei Li, Jie Jin, Weijun Fu, Zhihui Zhang, Zhen Cai, Hong Cen, Zhifeng Li, Yu Yang, Hui Zhou, Keshu Zhou, Junmin Li, Wei Zhang, Huijing Wu, Dengju Li, Li Zhang, Yuqin Song, Zhiming Li, Junning Cao, Hang Su, Lihua Qiu, Xiuhua Sun, Tingyu Wang
Subgroup analysis of (A) ORR, (B) DOR and (C) PFS confirmed by investigator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0374988e3c67e415c7591be1a3c9aff
https://doi.org/10.1158/1078-0432.22490801
https://doi.org/10.1158/1078-0432.22490801
Autor:
Jun Zhu, Jifeng Feng, Chunxia Chen, Weiwei Wang, Qingyuan Zhang, Hongwei Xue, Liling Zhang, Jun Luo, Jianda Hu, Haiwen Huang, Jie Jin, Yaozhong Zhao, Yanyan Liu, Junning Cao, Tongyu Lin, Xinchuan Chen, Jianqiu Wu, Yuqin Song
Purpose:For classical Hodgkin lymphoma (cHL), programmed death-l (PD-1) is a well-recognized attractive target. This multicenter, single-arm, phase II study evaluated the efficacy and safety of camrelizumab, a humanized high-affinity IgG4 mAb against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25e7346ea6d2aff4e3067fc943d8e232
https://doi.org/10.1158/1078-0432.c.6528162
https://doi.org/10.1158/1078-0432.c.6528162